We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Healthcare Inv | LSE:HIO | London | Ordinary Share | GB00B94T6Y14 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 14.75 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMCOS
Collagen Solutions PLC
08 May 2018
8 May 2018
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Collagen Solutions to Exhibit at 18(th) ESSKA Conference
"European Society of Sports Traumatology, Knee Surgery and Arthroscopy"
Dates: 9-12 May, SEEC, Glasgow
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, confirms that it will be exhibiting at the prestigious ESSKA conference being held in Glasgow between 9-12 May.
The ESSKA Congress, held every two years, is a major event in the pan-European calendar that brings together leading medical specialists, including orthopaedic surgeons, clinicians and scientists.
Collagen Solutions will be primarily highlighting the recent positive data reported for its most advanced regenerative proprietary product, ChondroMimetic(R), an arthroscopic, single-surgery, cost-effective solution for osteochondral defect repair. Earlier this year, the Company announced positive eight year follow-on data for ChondroMimetic(R) demonstrating durable cartilage regeneration in keyhole knee surgery. These results have allowed Collagen Solutions to begin the submission process to re-establish the CE Mark.
Commenting on the conference, Jamal Rushdy, CEO said: "We are delighted to be exhibiting at the pre-eminent ESSKA where we will be showcasing ChondroMimetic(R). This conference will give us the opportunity to actively engage with specialists and potential partners. Being able to demonstrate the key advantages of ChondroMimetic(R) over current therapies within this venue is a key part of our strategy of successfully commercialising ChondroMimetic(R)."
Collagen Solutions Plc Tel: +44 (0) 141 648 9100 Jamal Rushdy, Chief Executive Officer Hilary Spence, Chief Financial Officer Lisa Baderoon, Head of Investor Relations Tel: +44 (0) 7721 413 496 or lisa.baderoon@collagensolutions.com Cenkos Securities plc (NOMAD and Broker) Tel: +44 (0) 207 397 8900 Stephen Keys Steve Cox Walbrook PR Tel: +44 (0) 20 7933 8780 or collagen@walbrookpr.com Anna Dunphy Mob: +44 (0) 7876 741 001 Helen Cresswell
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com
What is ESSKA?
ESSKA represents Europe in the fields of degenerative disease and sports medicine. ESSKA achieves this by:
--Bringing together the practitioners: orthopaedic doctors, the surgeons and their various societies
--Fostering research and education, and the exchange of clinical and scientific information
--Organising courses, congresses and fellowship programmes
--Publishing its journals, books and newsletter to keep its members at the forefront of development
In all this, ESSKA's aim is to improve patients' quality-of-life, by improving the quality of their treatment.
For more information go to: www.esska.org
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAUSRKRWOAVRRR
(END) Dow Jones Newswires
May 08, 2018 02:01 ET (06:01 GMT)
1 Year Healthcare Inv Chart |
1 Month Healthcare Inv Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions